Currently there is no consensus for quantifying tau deposition on tau PET, and multiple tau-PET quantification methods (in vivo Braak staging, regional uptake in Braak composite regions, several whole-brain measures of tracer uptake, regional uptake in AD-vulnerable voxels and uptake in a priori defined regions) showed that all methods were related to amyloid and global cognition but regional measures covering AD-vulnerable regions increased sensitivity to early tau PET signal, atrophy and memory decline47. The gene discussed is MAPT; the disease is amyloidosis.